Cargando…
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis
INTRODUCTION: Proof of concept for local gene therapy for the treatment of arthritis with immunomodulatory cytokine interferon beta (IFN-β) has shown promising results in animal models of rheumatoid arthritis (RA). For the treatment of RA patients, we engineered a recombinant adeno-associated seroty...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479517/ https://www.ncbi.nlm.nih.gov/pubmed/26107769 http://dx.doi.org/10.1371/journal.pone.0130612 |
_version_ | 1782378023299842048 |
---|---|
author | Aalbers, Caroline J. Bevaart, Lisette Loiler, Scott de Cortie, Karin Wright, J. Fraser Mingozzi, Federico Tak, Paul P. Vervoordeldonk, Margriet J. |
author_facet | Aalbers, Caroline J. Bevaart, Lisette Loiler, Scott de Cortie, Karin Wright, J. Fraser Mingozzi, Federico Tak, Paul P. Vervoordeldonk, Margriet J. |
author_sort | Aalbers, Caroline J. |
collection | PubMed |
description | INTRODUCTION: Proof of concept for local gene therapy for the treatment of arthritis with immunomodulatory cytokine interferon beta (IFN-β) has shown promising results in animal models of rheumatoid arthritis (RA). For the treatment of RA patients, we engineered a recombinant adeno-associated serotype 5 vector (rAAV5) encoding human (h)IFN-β under control of a nuclear factor κB promoter (ART-I02). METHODS: The potency of ART-I02 in vitro as well as biodistribution in vivo in arthritic animals was evaluated to characterize the vector prior to clinical application. ART-I02 expression and bioactivity after transduction was evaluated in fibroblast-like synoviocytes (FLS) from different species. Biodistribution of the vector after local injection was assessed in a rat adjuvant arthritis model through qPCR analysis of vector DNA. In vivo imaging was used to investigate transgene expression and kinetics in a mouse collagen induced arthritis model. RESULTS: Transduction of RA FLS in vitro with ART-I02 resulted in high expression levels of bioactive hIFN-β. Transduction of FLS from rhesus monkeys, rodents and rabbits with ART-I02 showed high transgene expression, and hIFN-β proved bioactive in FLS from rhesus monkeys. Transgene expression and bioactivity in RA FLS were unaltered in the presence of methotrexate. In vivo, vector biodistribution analysis in rats after intra-articular injection of ART-I02 demonstrated that the majority of vector DNA remained in the joint (>93%). In vivo imaging in mice confirmed local expression of rAAV5 in the knee joint region and demonstrated rapid detectable and sustained expression up until 7 weeks. CONCLUSIONS: These data show that hIFN-β produced by RA FLS transduced with ART-I02 is bioactive and that intra-articular delivery of rAAV5 drives expression of a therapeutic transgene in the joint, with only limited biodistribution of vector DNA to other tissues, supporting progress towards a phase 1 clinical trial for the local treatment of arthritis in patients with RA. |
format | Online Article Text |
id | pubmed-4479517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44795172015-06-29 Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis Aalbers, Caroline J. Bevaart, Lisette Loiler, Scott de Cortie, Karin Wright, J. Fraser Mingozzi, Federico Tak, Paul P. Vervoordeldonk, Margriet J. PLoS One Research Article INTRODUCTION: Proof of concept for local gene therapy for the treatment of arthritis with immunomodulatory cytokine interferon beta (IFN-β) has shown promising results in animal models of rheumatoid arthritis (RA). For the treatment of RA patients, we engineered a recombinant adeno-associated serotype 5 vector (rAAV5) encoding human (h)IFN-β under control of a nuclear factor κB promoter (ART-I02). METHODS: The potency of ART-I02 in vitro as well as biodistribution in vivo in arthritic animals was evaluated to characterize the vector prior to clinical application. ART-I02 expression and bioactivity after transduction was evaluated in fibroblast-like synoviocytes (FLS) from different species. Biodistribution of the vector after local injection was assessed in a rat adjuvant arthritis model through qPCR analysis of vector DNA. In vivo imaging was used to investigate transgene expression and kinetics in a mouse collagen induced arthritis model. RESULTS: Transduction of RA FLS in vitro with ART-I02 resulted in high expression levels of bioactive hIFN-β. Transduction of FLS from rhesus monkeys, rodents and rabbits with ART-I02 showed high transgene expression, and hIFN-β proved bioactive in FLS from rhesus monkeys. Transgene expression and bioactivity in RA FLS were unaltered in the presence of methotrexate. In vivo, vector biodistribution analysis in rats after intra-articular injection of ART-I02 demonstrated that the majority of vector DNA remained in the joint (>93%). In vivo imaging in mice confirmed local expression of rAAV5 in the knee joint region and demonstrated rapid detectable and sustained expression up until 7 weeks. CONCLUSIONS: These data show that hIFN-β produced by RA FLS transduced with ART-I02 is bioactive and that intra-articular delivery of rAAV5 drives expression of a therapeutic transgene in the joint, with only limited biodistribution of vector DNA to other tissues, supporting progress towards a phase 1 clinical trial for the local treatment of arthritis in patients with RA. Public Library of Science 2015-06-24 /pmc/articles/PMC4479517/ /pubmed/26107769 http://dx.doi.org/10.1371/journal.pone.0130612 Text en © 2015 Aalbers et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Aalbers, Caroline J. Bevaart, Lisette Loiler, Scott de Cortie, Karin Wright, J. Fraser Mingozzi, Federico Tak, Paul P. Vervoordeldonk, Margriet J. Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis |
title | Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis |
title_full | Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis |
title_fullStr | Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis |
title_full_unstemmed | Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis |
title_short | Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis |
title_sort | preclinical potency and biodistribution studies of an aav 5 vector expressing human interferon-β (art-i02) for local treatment of patients with rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479517/ https://www.ncbi.nlm.nih.gov/pubmed/26107769 http://dx.doi.org/10.1371/journal.pone.0130612 |
work_keys_str_mv | AT aalberscarolinej preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT bevaartlisette preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT loilerscott preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT decortiekarin preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT wrightjfraser preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT mingozzifederico preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT takpaulp preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis AT vervoordeldonkmargrietj preclinicalpotencyandbiodistributionstudiesofanaav5vectorexpressinghumaninterferonbarti02forlocaltreatmentofpatientswithrheumatoidarthritis |